ArticlePLoS neglected tropical diseases2026
The cross-city mobility patterns and incubation period of the early-stage chikungunya fever outbreak in Guangdong Province, China, in 2025.
Article in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChikungunya fever (CF), an arthropod-borne disease caused by Chikungunya virus (CHIKV), is a serious public health threat globally. In July 2025, an outbreak occurred in Foshan City, Guangdong Province, China. A large number of these cases involved cross-city movements, which complicated containment efforts and provided a unique opportunity to study transmission patterns and key epidemiological parameters.
methodsWe obtained information on 400 confirmed cases of CF with cross-city exposure histories reported across Guangdong Province in southern China by 21 August 2025. Demographic, clinical, and mobility data were mainly obtained from the National Notifiable Infectious Disease Reporting System and supplemented by epidemiological investigations. The incubation period was estimated using a parametric accelerated failure time model, with log-normal, gamma, Weibull, and Erlang distributions used to fit the model. Subgroup analysis was performed based on mobility patterns and exposure windows. PRINCIPAL
findingsSignificant demographic differences were observed compared with local Foshan cases: cross-city cases had higher proportions of males (58.3%), individuals within the age groups of 15-24, 25-34, and 35-44,and individuals with occupations of general staff/workers, business/service workers, and students. Fever (86.4%), arthralgia (79.3%), and rash (61.2%) were the most common symptoms. Mobility analysis revealed that Foshan and Guangzhou were the major sources of infection, with cases spreading mainly to cities within the Pearl River Delta and provinces such as Guangxi (43.3%) and Hunan (15.4%). The median incubation period was estimated to be 5.4 days (95% CI 5.0-5.7), with 2.5th and 97.5th percentiles of 2.5 days and 11.4 days, respectively.
conclusionsThis study underscores the central role of population mobility in the spread of CHIKV and highlights distinct epidemiological characteristics of cross-city cases. The estimated median incubation period of 5.4 days provides important evidence for surveillance and response strategies during chikungunya outbreaks. Notably, students and migrant workers accounted for a higher proportion of cross-city cases, suggesting that highly mobile populations may contribute to inter-regional transmission. These findings highlight the importance of strengthened surveillance and coordination across regions for the prevention and control of future outbreaks in Guangdong and other high-risk areas in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.